Sreening and identification of serum specific aptamers for lung cancer
-
摘要:
目的 以磁珠为筛选介质,利用实时定量-PCR和消减SELEX技术从肺癌血清中筛选得到高特异性、强亲和力的肺癌血清核酸适配体。 方法 以磁珠为载体、肺癌病人血清为筛选的靶标分子,通过消减SELEX技术及实时定量PCR技术,从随机ssDNA文库中筛选出与肺癌血清特异性结合的aptamers,将得到的第9轮富集文库扩增为dsDNA,送上海生工直接对筛选得到的核酸适配体库进行高通量测序。 结果 经过9轮筛选得到4条与肺癌血清高特异性结合的aptamers,测序结果显示均为不同序列。 结论 验证筛选出的与肺癌血清结合的aptamer,特异性检测表明,筛选得到的肺癌血清核酸适配体与肺癌血清的结合解离常数均在纳摩尔级水平,其中Seq-2、Seq-3、Seq-6、Seq-19号核酸适配体能高特异性结合肺癌血清,与正常人血清不结合,再通过200例肺癌血清和200例正常人血清进一步鉴定4条肺癌血清核酸适配体检出肺癌的阳性率,阳性检出率达91%以上,为肺癌的早期诊断提供了新方法。 Abstract:Objective To obtain high-specificity and strong-affinity serum aptamer of lung cancer from lung cancer serum by real-time quantitative PCR and subtractive SELEX technology, with magnetic beads as the screening medium. Methods Using magnetic beads as the carrier and the serum of lung cancer patients as the screening target molecule, aptamers that bind to the sera of lung cancer were screened from the random ssDNA library by SELEX and real-time quantitative PCR. Then the obtained 9th round enriched library was amplified to dsDNA and sent to Sangon Biotech (Shanghai), where the screened library of aptamers went through high-throughput sequencing. Results After four rounds of screening, four aptamers with high specificity of serum were obtained. The sequencing results showed that they were different sequences. Conclusion The specificity of screened aptamer in combination with serum of lung cancer was tested. The results showed that the binding dissociation constants of serum aptamer and lung cancer serum were all within nanomolar level. Seq-2, Seq-3, Seq-6 and Seq-19 can bind to the serum of lung cancer with high specificity, but not with normal human serum. Using the serum of 200 cases of lung cancer and normal human serum of 200 cases, it was showed that the positive detection rate of lung cancers by these four serum aptamers of lung cancers could reach 91% or even higher, thus providing a new method for the early diagnosis of lung cancer. -
Key words:
- subductive SELEX technique /
- magnetic beads /
- lung cancer serum /
- aptamer
-
表 1 肺癌血清核酸适配体SELEX筛选条件
轮次 磁珠量(mL) 收获ssDNA文库量(pmol) ssDNA文库量(pmol) 肺癌混合血清量(μL) 文库/磁珠结合血清 孵育时间(min) 1 1 69.5 69.5 600 2 60 2 1 46.3 46.3 300 2 60 3 0.5 79.8 52 350 4 50 4 0.5 59.7 50 300 4 50 5 0.3 42.9 40 275 6 50 6 0.25 51.6 45 250 6 40 7 0.2 49.1 40 225 8 40 8 0.15 30.1 30 200 8 40 9 0.10 28.1 28 175 10 30 表 2 肺癌血清核酸适配体序列
适配体 核酸序列 丰度(%) Kd(nmol/L) Seq-2 5′-CTATAGCAATGGTACGGTACTTCCCAATGGTACGGTACTTCCAA
GCTAACCCTCATCTGCGCGCCAAAAGTGCACGCTACTTTGCTAA-3′16 22±7.2 Seq-3 5′-CTATAGCAATGGTACGGTACTTCCCCTCGGCACGTTCTCAGTAG
CGCTCGCTGGTCATCCCACACAAAAGTGCACGCTACTTTGCTAA-3′13 29±8.9 Seq-6 5′-CTATAGCAATGGTACGGTACTTCCCCAAGCTAACCCCCATCTG
CGCGCTCCTCAGTAGCGCTGCCAAAAGTGCACGCTACTTTGCTAA-3′15 35±6.3 Seq-19 5′-CTATAGCAATGGTACGGTACTTCCATGGTACGGTACTTCCAAG
CTAACCCCCATCTGCGCGCTCCAAAAGTGCACGCTACTTTGCTAA-3′20 15±8.6 Seq-25 5′-CTATAGCAATGGTACGGTACTTCCAAGCTAACCCTCATCCGCG
CGCTCCCCAAGCAGTATGCGCCAAAAGTGCACGCTACTTTGCTAA-3′4 76±8.4 Seq-32 5′-CTATAGCAATGGTACGGTACTTCCTACGACTCACTATAGGAGCT
AACCC TCATCTGCGCGCTCCCAAAAGTGCACGCTACTTTGCTAA-3′2 106±7.2 Seq-51 5′-CTATAGCAATGGTACGGTACTTCCAAGCTGACCCTCATCTGCGC
GCTC CACCCTCATCTACGCGCAAAAGTGCACGCTACTTTGCTAA-3′3.5 109±4.9 Seq-54 5′-CTATAGCAATGGTACGGTACTTCCAAGCTAACCCTCATCTGCAC
GTATCGGCTCTGGTAAGGTCCAAAAGTGCACGCTACTTTGCTAA-3′3 125±7.4 Seq-69 5′-CTATAGCAATGGTACGGTACTTCCGGACGCGGTTAGGGGAGAA
TTTCCATACCTTTGGGTTGTACAAAAGTGCACGCTACTTTGCTAA-3′1.5 99±4.6 Seq-76 5′-CTATAGCAATGGTACGGTACTTCCCTTTGTGCGGCCTGCAGCCG
TAGTAGTTGGTTTAACGCGTCAAAAGTGCACGCTACTTTGCTAA-3′1 89±6.9 -
[1] Kim MC, Van Mierlo, Frank G.Liver resection for cancer:new developments in prediction,prevention and management of postresectional liver failure[J]. J Hepatol, 2016, 65(6): 1217-31. [2] Yim WW, Kwan SW, Yetisgen M. Tumor reference resolution and characteristic extraction in radiology reports for liver cancer stage prediction[J]. J Biomed Inform, 2016, 64(4): 179-91. [3] Sasaki T, Kuniyasu H, Luo Y, et al. Serum CD10 is associated with liver metastasis in colorectal cancer[J]. J Surg Res, 2014, 192(2): 390-4. [4] Barrachina L, Remacha AR, Soler L, et al. Acute phase protein haptoglobin as inflammatory marker in serum and synovial fluid in an equine model of arthritis[J]. Vet Immunol Immunopathol, 2016, 182(8): 74-8. [5] Sauzay C, Petit A, Bourgeois AM, et al. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma[J]. Clin Chim Acta, 2016, 463(1): 39-44. [6] Gong X, Yan H, Yang J, et al. High-performance fluorescence-encoded magnetic microbeads as microfluidic protein chip supports for AFP detection[J]. Anal Chim Acta, 2016, 93(9): 84-92. [7] Zhuang B, Zhang Y, Peng J, et al. Effect of recombinant plasmid pEGFP-AFP-hTNF on liver cancer cells (HepG2 Cells) in vitro when delivered by PEG-PEI/Fe3O4 nanomagnetic fluid[J]. J Form Med Assoc, 2011, 110(5): 326-35. [8] Djordjevic M. SELEX experiments: New prospects, applications and data analysis in inferring regulatory pathways[J]. Biomol Eng, 2007, 24(2): 179-89. [9] Geczy CL, Goyette J, Lim SY, et al. Inflammation-associated S100 proteins: new mechanisms that regulate function[J]. Amino Acids, 2009, 37(1, S): 77-82. [10] Ji Y, Wang QQ, Fu J, et al. Optimization of polymerase chains reaction amplification for ssDeoxyribonucleic acid library using capillary electrophoresis with laser-induced fluorescence detection[J]. Chinese J Anal Chem, 2010, 38(5): 622-6. [11] Ni X, Castanares M, Mukherjee A, et al. Nucleic acid aptamers: clinical applications and promising new horizons[J]. Curr Med Chem, 2011, 18(27): 4206-14. [12] 葸玉琴, 赵运旺, 李东东, 等. 胃癌血清适配体的筛选及其鉴定[J]. 南京医科大学学报:自然科学版, 2016, 36(11): 1306-12. [13] Du J, Yang SY, Lin XL, et al. Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer[J]. Diagn Pathol, 2010, 5(11): 60-5. [14] Szczyrba J, Loeprich E, Wach S, et al. The MicroRNA profile of prostate carcinoma obtained by deep sequencing[J]. Mol Cancer Res, 2010, 8(4): 529-38. [15] Willner I, Zayats M. Electronic aptamer-based sensors[J]. Angew Chem Int Ed Engl, 2007, 46(34): 6408-18. [16] Takahashi M, Sakota E, Nakamura Y. The efficient cell-SELEX strategy, Icell-SELEX, using isogenic cell lines for selection and counter-selection to generate RNA aptamers to cell surface proteins[J]. Biochimie, 2016, 131(12): 77-84. [17] Wu YX, Kwon YJ. Aptamers: the " evolution” of SELEX[J]. Methods, 2016, 106(15): 21-8. [18] Hoinka J, Przytycka T. AptaPLEX - A dedicated, multithreaded demultiplexer for HT-SELEX data[J]. Methods, 2016, 106(15): 82-5. [19] Moghadam M, Sankian M, Abnous K, et al. Cell-SELEX-based selection and characterization of a G-quadruplex DNA aptamer against mouse dendritic cells[J]. Int Immunopharmacol, 2016, 36(5): 324-32. [20] Kang DZ, Wang JJ, Zhang WY, et al. Selection of DNA aptamers against glioblastoma cells with high affinity and specificity[J]. PLoS One, 2012, 7(10): e42731-6. [21] Zamay GS, Kolovskaya OS, Zamay TN, et al. Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood[J]. Mol Ther, 2015, 23(9): 1486-96. [22] Clawson GA, Abraham T, Pan WH, et al. A cholecystokinin B Receptor-Specific DNA aptamer for targeting pancreatic ductal adenocarcinoma[J]. Nucleic Acid Ther, 2017, 27(1): 23-35. [23] Yoon S, Huang KW, Reebye V, et al. Targeted delivery of C/EBPalphasaRNA by pancreatic ductal adenocarcinoma-specific RNA aptamers inhibits tumor growth in vivo[J]. Mol Ther, 2016, 45(24): 1106-16. [24] Alibolandi M, Taghdisi SM, Ramezani P, et al. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo[J]. Int J Pharm, 2017, 519(1/2): 352-64. [25] Chen M, Yu Y, Jiang F, et al. Development of Cell-SELEX technology and its application in cancer diagnosis and therapy[J]. Int J Mol Sci, 2016, 17(12): 362-7. [26] Wu XQ, Zhao ZL, Bai HR, et al. DNA aptamer selected against pancreatic ductal adenocarcinoma for in vivo imaging and clinical tissue recognition[J]. Theranostics, 2015, 5(9): 985-94. [27] Zueva E, Rubio LI, Duconge F, et al. Metastasis-focused cell-based SELEX generates aptamers inhibiting cell migration and invasion[J]. Int J Cancer, 2011, 128(4): 797-804. [28] Mckeague M, De Girolamo A, Valenzano SA, et al. Comprehensive analytical comparison of strategies used for small molecule aptamer evaluation[J]. Anal Chem, 2015, 87(17): 8608-12. [29] Li N, Ebright JN, Stovall GM, et al. Technical and biological issues relevant to cell typing with aptamers[J]. J Proteome Res, 2009, 8(5): 2438-48. [30] Wang R, Li Y. Hydrogel based QCM aptasensor for detection of avian influen zavirus[J]. Biosens Bioelectron, 2013, 79(42): 148-55.